Infectious Diseases: R&D Challenges and Market Drivers

Table of Contents

CHAPTER 1

NEW MICROBIAL DEMANDS AND MAJOR DRIVERS OF THE ANTI-INFECTIVE MARKETPLACE

• 1.1. The Emergence, Re-emergence, and Spread of Infectious Diseases
• 1.2. The Very Serious Problem of Drug Resistance
• 1.3. Biodefense
• 1.4. Technological Growth and Increased Knowledge
• 1.5. Growing Concerns about Food Safety
• 1.6. Animal Health
• 1.7. The Infectious Etiology of Chronic Diseases

CHAPTER 2

THERAPEUTIC CHALLENGES: MICROBES AS MOVING TARGETS

• 2.1. Introduction
• 2.2. HIV/AIDS Antiretrovirals: Growth in a Mature Market
• 2.3. Adding to the Antibiotic Arsenal
  • Phage Therapy: A New Market Niche for Alternative Antibacterials?
• 2.4. Bird Flu
  • The Current Avian Influenza A (H5N1) Outbreak
  • Influenza Therapeutics
  • Oseltamivir (Tamiflu)
• 2.5. Retroviruses: A Global Threat More Serious Than Influenza?
• 2.6. Vaccine Industry Challenges
  • Infectious Agent Vaccines for the Prevention of Chronic Disease
  • Human Papilloma Virus Vaccines
  • Changing Trends in Vaccine Technology and Targets
  • New Vaccine Targets
  • The Race To Make a Universal Influenza Vaccine
  • M2 Vaccines
  • NP Vaccines
  • When Will Plant-Based Vaccines Be Ripe for Marketing?

CHAPTER 3

DOING THE DETECTIVE WORK: INFECTIOUS DISEASE DIAGNOSTICS

• 3.1. Introduction
• 3.2. Molecular Diagnostics
  • Advantages of Molecular Versus Culture-Based Detection
  • Human Papilloma Virus Testing: The Fastest-Growing Molecular Diagnostic Test
  • HIV and HCV Viral Load Tests
  • HCV Testing
• 3.3. Blood Safety: The Emerging Problem of Bacterial Contamination
  • Other Blood-Borne Pathogens of Concern
  • The Emerging Problem of Transfusion-Associated Bacterial Contamination
• 3.4. The 2003 to 2006 Avian Influenza Outbreak: The Importance of Rapid Diagnostic Testing
  • Prompt Treatment
  • Surveillance and WHO Notification
  • Preventing Dissemination and Opportunities for Viral Evolution
  • The Ideal Influenza Test
  • Available Avian Influenza Diagnostic Tests
  • PCR-Based Nucleic Acid Amplification Tests
  • Commercial Availability of "Rapid" Tests Still Requiring Validation

CHAPTER 4

COMMERCIAL OPPORTUNITIES: COMFORTABLE NICHES EXIST FOR BOTH BIG PHARMA AND SMALL BIOTECHS

• 4.1. Introduction
• 4.2. Patent Expiration and Price Drops
• 4.3. Antimicrobial Resistance and Market Opportunities
  • Products and Profitability: Major and Small-Company Players
• 4.4. Biodefense: A Call to Industry
  • Opportunities and Challenges for Small Companies Seeking Government Biodefense Contracts
  • Companies on Government Contract
  • Finding the Funds
  • Efforts to Strengthen BioShield: Looking to Large Pharma
• 4.5. The Present and Future Burden of Infectious Disease
• 4.6. Finding Your Market Niche
• 4.7. Neglected Infectious Disease Drug Development: Opportunities for All, Big and Small
  • Major Neglected Infectious Diseases
  • Malaria
  • Tuberculosis
  • Onchocerciasis
  • Dengue
  • Visceral Leishmaniasis
  • Lymphatic Filariasis
• 4.8. Collaboration and Consolidation
• 4.9. The Biggest Challenge Is Basic Science: The Red Queen Race

CHAPTER 5

COMPANY PROFILES

• 5.1. Acambis
• 5.2. Adlyfe Inc.
• 5.3. Akonni Biosystems
• 5.4. Alnylam Pharmaceuticals
• 5.5. Arbor Vita Corporation
• 5.6. Biophage Pharma Inc.
• 5.7. CEL-SCI Corporation
• 5.8. CombiMatrix Corporation
• 5.9. Cubist Pharmaceuticals, Inc.
• 5.10. Gilead Sciences, Inc.
• 5.11. NanoBio Corporation
• 5.12. Nanosphere, Inc.
• 5.13. Obetech, LLC
• 5.14. Panacos Pharmaceuticals, Inc.
• 5.15. PowderMed Limited
• 5.16. Progenics Pharmaceuticals, Inc.
• 5.17. Ribomed Biotechnologies, Inc.
• 5.18. Tanox, Inc.
• 5.19. Targanta Therapeutics, Inc.
• 5.20. Tm Bioscience Corporation

APPENDIX

CHA ADVANCES INFECTIOUS DISEASE SURVEY - July/August 2006 (n = 83)

References

Glossary

Company Index with Web Sites